← Back
Data updated: Mar 10, 2026
CUMBERLAND
RespiratoryCardiovascularImmunology
CUMBERLAND is a specialty pharmaceutical company focused on Respiratory, Cardiovascular, Immunology.
2005
Since
5
Drugs
-
Trials
2
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Respiratory 33%
0 drugs Phase 2: 2
Cardiovascular 33%
0 drugs Phase 2: 2
Immunology 17%
0 drugs Phase 2: 1
Dermatology 17%
0 drugs Phase 2: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Novartis big-pharma
Cardiovascular, Immunology, Respiratory
BAUSCH specialty
Dermatology, Immunology, Cardiovascular
AstraZeneca big-pharma
Respiratory, Cardiovascular, Immunology
COREPHARMA other
Cardiovascular, Respiratory, Immunology, Dermatology
COSETTE other
Cardiovascular, Dermatology, Immunology
Discontinued (2)
Company Info
- First Approval
- 2005-12-29
- Latest
- 2024-09-16
- Applications
- 4